| 000 | 02808 a2200757 4500 | ||
|---|---|---|---|
| 005 | 20250514205923.0 | ||
| 264 | 0 | _c20050314 | |
| 008 | 200503s 0 0 eng d | ||
| 022 | _a0364-5134 | ||
| 024 | 7 |
_a10.1002/ana.20296 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAubert, Incarnation | |
| 245 | 0 | 0 |
_aIncreased D1 dopamine receptor signaling in levodopa-induced dyskinesia. _h[electronic resource] |
| 260 |
_bAnnals of neurology _cJan 2005 |
||
| 300 |
_a17-26 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine _xpharmacology |
| 650 | 0 | 4 |
_a2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine _xpharmacology |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aAutoradiography _xmethods |
| 650 | 0 | 4 | _aBehavior, Animal |
| 650 | 0 | 4 |
_aBlotting, Western _xmethods |
| 650 | 0 | 4 | _aCyclin-Dependent Kinase 5 |
| 650 | 0 | 4 | _aCyclin-Dependent Kinases |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDopamine Plasma Membrane Transport Proteins |
| 650 | 0 | 4 | _aDopamine and cAMP-Regulated Phosphoprotein 32 |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xetiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGuanosine 5'-O-(3-Thiotriphosphate) _xpharmacokinetics |
| 650 | 0 | 4 |
_aImmunohistochemistry _xmethods |
| 650 | 0 | 4 |
_aIn Situ Hybridization _xmethods |
| 650 | 0 | 4 |
_aIsotopes _xpharmacokinetics |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 | _aMacaca fascicularis |
| 650 | 0 | 4 |
_aMembrane Glycoproteins _xmetabolism |
| 650 | 0 | 4 |
_aMembrane Transport Proteins _xmetabolism |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aNerve Tissue Proteins _xmetabolism |
| 650 | 0 | 4 |
_aNortropanes _xpharmacokinetics |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aPhosphoproteins _xmetabolism |
| 650 | 0 | 4 |
_aRadioligand Assay _xmethods |
| 650 | 0 | 4 |
_aReceptors, Dopamine D1 _xagonists |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xgenetics |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aSubstantia Nigra _xdrug effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aGuigoni, Céline | |
| 700 | 1 | _aHåkansson, Kerstin | |
| 700 | 1 | _aLi, Qin | |
| 700 | 1 | _aDovero, Sandra | |
| 700 | 1 | _aBarthe, Nicole | |
| 700 | 1 | _aBioulac, Bernard H | |
| 700 | 1 | _aGross, Christian E | |
| 700 | 1 | _aFisone, Gilberto | |
| 700 | 1 | _aBloch, Bertrand | |
| 700 | 1 | _aBezard, Erwan | |
| 773 | 0 |
_tAnnals of neurology _gvol. 57 _gno. 1 _gp. 17-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ana.20296 _zAvailable from publisher's website |
| 999 |
_c15203388 _d15203388 |
||